Tildrakizumab Treatment Patterns in Adults With Moderate-to-Severe Plaque Psoriasis: A Retrospective Analysis From the Canadian Patient Support Program.

INTRODUCTION

Tildrakizumab is an anti-interleukin-23 p19 monoclonal antibody approved in several countries to treat adult patients with moderate-to-severe plaque psoriasis who are candidates for phototherapy or systemic therapy. Limited data are available on tildrakizumab treatment patterns in clinical practice. The Canadian tildrakizumab patient support program (PSP), which provides personalized reimbursement, financial aid, and injection training support for disease management, was used in this study to evaluate real-world persistence and adherence to tildrakizumab.

METHODS

This retrospective, observational study used data collected in the Canadian tildrakizumab PSP database between August 4, 2021, and August 1, 2023. Adult (≥18 years) patients with moderate-to-severe plaque psoriasis who enrolled in the PSP and received ≥6 months of treatment with tildrakizumab before August 1, 2023, were included. Data up to Week 52 following treatment initiation were analyzed. Persistence was defined as the number of days until treatment discontinuation. Adherence was measured as the proportion of days covered (PDC) from treatment initiation to treatment discontinuation or study cutoff, with PDC ≥80% indicating high adherence.

RESULTS

The study included 813 patients with a mean ± standard deviation (SD) age of 49.6 ± 15.9 years; 55.0% (447/813) were male, and 92.7% (754/813) were biologic-naïve when initiating tildrakizumab. Patients received tildrakizumab treatment for a mean ± SD of 329.6 ± 55.0 days. After 1 year, 88.0% of patients were persistent on treatment. Adherence was also high, with mean ± SD PDC being 97.5% ± 8.9% and 93.5% of patients having PDC ≥80%. Eighty-five patients discontinued treatment, primarily because of switching to other therapies. Common adverse outcomes included treatment misuse (18.9%), disease flare (8.2%), and treatment discontinuation (7.4%).

CONCLUSION

Persistence and adherence to tildrakizumab were high through 52 weeks of treatment among patients with moderate-to-severe plaque psoriasis enrolled in the Canadian PSP.